Illumina slides as China bans imports of its gene sequencers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- UBS sees generational semiconductor boom, highlights stock winners
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
March 4, 2025 12:52 PM ESTCanaccord Genuity analyst Kyle Mikson reiterated a Hold rating and $135.00 price target on Illumina (NASDAQ: ILMN).
The analyst comments "We reiterate our HOLD rating on Illumina (ILMN) shares and maintain our price target at $135. Before the market open on Tuesday, March 4, China's Ministry of Commerce (MOFCOM)... More
Barclays Reiterates Underweight Rating on Illumina (ILMN), PT $100
March 4, 2025 10:06 AM ESTBarclays analyst Luke Sergott reiterated an Underweight rating and $100.00 price target on Illumina (NASDAQ: ILMN).
The analyst comments "The biggest fear for Tools investors re China tariffs is on how China retaliates. The first shot, indicated weeks ago (see our report HERE, as well as the Reuters article HERE), hits ILMN, with China announcing a ban in effect starting today. On first... More
Evercore ISI Reiterates Outperform Rating on Illumina (ILMN)
March 4, 2025 9:57 AM ESTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $160.00 price target on Illumina (NASDAQ: ILMN)
The analyst comments "Bottomline: Policy uncertainty makes it hard for businesses to investand ILMNs ~40% slide in past month has captured it relative to others. We think ILMN should find support once China news gets priced in. Our Take #1: Assuming zero China revs, EPS HW could be ~50c (assuming no cost actions) As seen from Fig 1, we assumed China OM to be double that of corporate... More
Stifel Reiterates Buy Rating on Illumina (ILMN)
March 4, 2025 9:52 AM ESTStifel analyst Daniel Arias reiterated a Buy rating and $160.00 price target on Illumina (NASDAQ: ILMN).
The analyst comments "One month after adding ILMN to the unreliable entities list as an act of retaliation against the US increasing tariffs on China, China today announced that a penalty for being on that list for ILMN is they are now prohibited from exporting gene sequencers to China. This does not appear to prohibit sales of consumables or services to the region, which represents the vast majority of ILMN's China revenues. ILMN management had stated... More
Wolfe Research Reiterates Outperform Rating on Illumina (ILMN), PT $150
March 4, 2025 9:51 AM ESTWolfe Research analyst Doug Schenkel reiterated an Outperform rating and $150.00 price target on Illumina (NASDAQ: ILMN)
The analyst comments "Overnight, China banned ILMN from importing sequencers into the country. The company is working to assess the potential impact and continues to... More
Leerink Partners on Illumina (ILMN), 'optics is likely to affect customer willingness to buy'
March 4, 2025 9:45 AM ESTLeerink Partners analyst Puneet Souda reiterated an Outperform rating and $150.00 price target on Illumina (NASDAQ: ILMN)
The analyst comments "Bottom Line: This morning, China announced a ban on importing ILMN's sequencers. The action is unlikely to come as a surprise and part of retaliatory actions after China placed ILMN on the Unreliable Entity List (UEL) in early February. ILMN kept the China revenue intact after the prior UEL announcements - citing... More
